Statement re Selection to Participate in Research Project
March 04 2021 - 7:00AM
Statement re Selection to Participate in Research Project
DXS INTERNATIONAL PLC
(AQSE: DXSP)
Selection to Participate in Research
Project
DXS International plc ("DXS" or the "Company"),
the digital clinical decision support Company, is pleased to
announce that David Immelman and Steven Bauer will provide a live
presentation relating to an overview of DXS International with
emphasis on ExpertCare, the new Chronic Disease Management solution
which currently focuses on hypertension, via the Investor Meet
Company platform on 5th March 2021 at 10:00am. The Company will
also give an update on its Point-of-Care, CompleteCare and
MyVytalCare products.
DXS International plc ("DXSP", the "Company"), the AQSE quoted
clinical decision support developer and supplier of clinical
decision support systems, is pleased to announce that it has been
selected to receive a grant to take part in a Pre-Commercial
Procurement project by HSMonitor.
HSMonitor is a Pre-Commercial Procurement (PCP) project
investing in Research and Development services towards innovative
ICT-enabled monitoring solutions to improve health status and
optimise hypertension care. The initiative is funded by the
European Union’s Horizon Research and Development programme that
seeks to drive and support innovation in member states. Five
healthcare providers from four countries are engaged in the
procurement, catering to a combined population of over 96 million
people, of which over 31 million have hypertension.
A Call for Tenders was launched in August 2020, calling for
innovative ideas to be proposed. A total of 18 Tenders were
submitted to the Call, representing 70 participating entities from
16 countries, the majority of which represent Small and
Medium-sized Enterprises (SMEs). Following a thorough evaluation of
the submitted bids, seven projects were selected to proceed in
Phase I of the R&D process.The envisaged solutions are to be
developed in three funded competitive phases and further detail can
be found on the HSMonitor website https://hsmonitor-pcp.eu . The
PCP is anticipated to roll out over a twenty-five month period.
Chief Executive David Immelman commented:
“I am delighted that the DXS’ team’s hard work, dedication and
expertise have been rewarded by this selection in the face of stiff
opposition. This is an exciting time for DXS to help improve
patient outcomes by bringing our Long-Term Condition management
healthcare solutions to a new market – particularly as the next
phase of development will now be supported by grant funding. Our
Hypertension solution, in which we have invested over a number of
years, will provide improved outcomes and significant efficiency
savings for all hypertension sufferers in Europe, as well as for
both GP Practices and the NHS in the UK.
While going forward to Phases II and III is by selection, we are
confident that our expertise and depth of knowledge will ensure our
offering is of the highest standard.”
The Directors of DXS International plc accept
responsibility for this announcement.
Contacts:
David
Immelman (Chief
Executive)DXS International plc |
01252 719800david@dxs-systems.com |
https://www.dxs-systems.co.uk |
|
Corporate
Advisor |
|
City &
Merchant David Papworth |
020 7101 7676 |
Corporate
Broker |
|
Hybridan
LLPClaire Louise Noyce |
020 3764 2341 |
Notes to Editors
About DXS:
DXS International presents up to date treatment
guidelines and recommendations, from Clinical Commissioning Groups
and other trusted NHS sources, to doctors, nurses and pharmacists
in their workflow and during the patient consultation. This
effective clinical decision support ultimately translates to
improved healthcare outcomes delivered more cost effectively and
which should significantly contribute towards the NHS achieving its
projected efficiency savings.
DXS (AQSE:DXSP)
Historical Stock Chart
From Jun 2024 to Jul 2024
DXS (AQSE:DXSP)
Historical Stock Chart
From Jul 2023 to Jul 2024